AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9805117 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced injectate
Number of subjects: 50
Study 9805117 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature injectate
Number of subjects: 50
Study 7621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 5098
Study 7621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 5098
Study 7621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable No. 1
Number of subjects: 5098
Study 7621686 — intervention group
Group type: COMPARATOR
Intervention: Mesigyna vs Cyclofem
Number of subjects: 5098
Study 2133202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instruments
Number of subjects: 50
Study 2133202 — intervention group
Group type: EXPERIMENTAL
Intervention: Roto-pro instruments
Number of subjects: 50
Study 2133202 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 50
Study 378315 — intervention group
Group type: EXPERIMENTAL
Intervention: High vacuum Redivac drains
Number of subjects: 46
Study 378315 — intervention group
Group type: COMPARATOR
Intervention: Low vacuum Portovac drains
Number of subjects: 46
Study 31190476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin vaccination
Number of subjects: 1241
Study 31190476 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis
Number of subjects: 1241
Study 31190476 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitization
Number of subjects: 1241
Study 31190476 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis in sensitized children
Number of subjects: 1241
Study 28968759 — intervention group
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA delivered intramuscularly by Biojector
Number of subjects: 100
Study 28968759 — intervention group
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA delivered intramuscularly by CELLECTRA electroporation device
Number of subjects: 100
Study 28968759 — intervention group
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA followed by MVA-CMDR boost
Number of subjects: 100
Study 25883095 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Number of subjects: 145
Study 25883095 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 145
Study 23576032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored post‐operative physiotherapy programme
Number of subjects: 80
Study 23576032 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 80
Study 21286810 — intervention group
Group type: EXPERIMENTAL
Intervention: Click City®: Tobacco
Number of subjects: 47
Study 21286810 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum
Number of subjects: 47
Study 18986859 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI 1
Number of subjects: 79
Study 18986859 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI 2
Number of subjects: 79
Study 18986859 — intervention group
Group type: EXPERIMENTAL
Intervention: Perlane
Number of subjects: 79
Study 18986859 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyplast
Number of subjects: 79
Study 17234439 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine iontophoresis
Number of subjects: 10
Study 17234439 — intervention group
Group type: COMPARATOR
Intervention: Saline iontophoresis
Number of subjects: 10
Study 17234439 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid injection
Number of subjects: 10
Study 17234439 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 10
Study 15509420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 96
Study 15509420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 96
Study 15509420 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 96
Study 11694687 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 1109
Study 11694687 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 1109
Study 9134635 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 16
Study 7956552 — intervention group
Group type: EXPERIMENTAL
Intervention: MOM nutrient powder (30 g/day)
Number of subjects: 90
Study 7956552 — intervention group
Group type: COMPARATOR
Intervention: Iron, folic acid, calcium, vitA+D
Number of subjects: 90
Study 2892349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin, 10 mg b.i.d.
Number of subjects: 13
Study 2892349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 1,200 mg QD
Number of subjects: 114
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg BD
Number of subjects: 114
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg QD
Number of subjects: 114
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 300 mg BD
Number of subjects: 114
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 300 mg QD
Number of subjects: 114
Study 31988102 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 1,200 mg TIW
Number of subjects: 114
Study 31988102 — intervention group
Group type: COMPARATOR
Intervention: Combination of isoniazid, rifampin, pyrazinamide, and ethambutol
Number of subjects: 114
Study 29789278 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning program for 6 months
Number of subjects: 269
Study 27903518 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW PRO diet (0.7 g · kg‐1 · d‐1)
Number of subjects: 24
Study 27903518 — intervention group
Group type: COMPARATOR
Intervention: HIGH PRO diet (1.5 g · kg‐1 · d‐1)
Number of subjects: 24
Study 25612882 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of raw flaxseed powder every day for 40 days
Number of subjects: 70
Study 25612882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flaxseed intervention)
Number of subjects: 70
Study 23419887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted mindfulness-based stress reduction (MBSR)
Number of subjects: 105
Study 23419887 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 105
Study 20153132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Programme (CDSMP)
Number of subjects: 317
Study 19189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-care ward
Number of subjects: 238
Study 19189601 — intervention group
Group type: COMPARATOR
Intervention: Inpatient ward
Number of subjects: 238
Study 19189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 238
Study 15666380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 62
Study 15666380 — intervention group
Group type: COMPARATOR
Intervention: Standard recovery (STD)
Number of subjects: 62
Study 12623805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin
Number of subjects: 423
Study 12623805 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ofloxacin
Number of subjects: 423
Study 10585031 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized ITA graft
Number of subjects: 40
Study 10585031 — intervention group
Group type: COMPARATOR
Intervention: Pedicled ITA graft
Number of subjects: 40
Study 8948268 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (100 micrograms/day)
Number of subjects: 20
Study 8948268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate membrane (Duo‐Flux, Cordis‐Dow)
Number of subjects: 10
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane (Filtral 12, Hospal)
Number of subjects: 10
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan (GFS 120 Plus, Gambro)
Number of subjects: 10
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (F6, Fresenius)
Number of subjects: 10
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprammonium (AM50‐BIO, Asahi)
Number of subjects: 10
Study 1766495 — intervention group
Group type: EXPERIMENTAL
Intervention: Other membranes
Number of subjects: 10
Study 7465620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluori‐Methane spray and static passive stretch
Number of subjects: 30
Study 7465620 — intervention group
Group type: COMPARATOR
Intervention: Static passive stretch
Number of subjects: 30
Study 30928279 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) treatment for 1 week
Number of subjects: 27
Study 30928279 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 1 week
Number of subjects: 27
Study 28097626 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentors delivering a physical activity intervention
Number of subjects: 76
Study 25935101 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-related acupoints (eye-points)
Number of subjects: 22
Study 25935101 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eye-related acupoints (non-eye-points)
Number of subjects: 22
Study 23851969 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 67
Study 23851969 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 67
Study 21383392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 53
Study 21383392 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 53
Study 19429570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (gym followed by telephone-monitored home-based exercise training)
Number of subjects: 223
Study 19429570 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 223
Study 18201582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of telmisartan 40 mg + amlodipine 5 mg (T+A)
Number of subjects: 210
Study 18201582 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg monotherapy (A)
Number of subjects: 210
Study 18201582 — intervention group
Group type: EXPERIMENTAL
Intervention: T+A
Number of subjects: 210
Study 18201582 — intervention group
Group type: COMPARATOR
Intervention: A
Number of subjects: 210
Study 14504682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg once daily)
Number of subjects: 187
Study 14504682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 11115423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 140
Study 11115423 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 140
Study 9450174 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen ultrafiltrate (Prosplen)
Number of subjects: 26
Study 9450174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7840861 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 12
Study 7840861 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg tropisetron
Number of subjects: 12
Study 7840861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3048759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (1800 mg for 3 days)
Number of subjects: 50
Study 3048759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (1500 mg and 75 mg, respectively)
Number of subjects: 50
Study 3048759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine
Number of subjects: 50
Study 3048759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine-pyrimethamine
Number of subjects: 50
Study 31128268 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CTP) adjunctive to methylphenidate (MPH)
Number of subjects: 49
Study 31128268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) adjunctive to methylphenidate (MPH)
Number of subjects: 49
Study 29606549 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal crescentic osteotomy (PCO)
Number of subjects: 57
Study 29606549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational scarf osteotomy
Number of subjects: 57
Study 28800778 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP values determined during a static pulmonary compliance (Cstat)‐directed PEEP titration procedure
Number of subjects: 40
Study 28800778 — intervention group
Group type: COMPARATOR
Intervention: Standard lung‐protective ventilation with a PEEP of 6 cmH2O
Number of subjects: 40
Study 26273612 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 26
Study 26273612 — intervention group
Group type: COMPARATOR
Intervention: Control (no L-PRF)
Number of subjects: 26
Study 24285128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate hydration
Number of subjects: 142
Study 24285128 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline hydration
Number of subjects: 142
Study 20835903 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 105
Study 20835903 — intervention group
Group type: COMPARATOR
Intervention: Control group (rejection of ASV treatment or usage <50% of nights possible and/or <4 h/night; n = 59)
Number of subjects: 105
Study 19033511 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical attire
Number of subjects: 24
Study 19033511 — intervention group
Group type: COMPARATOR
Intervention: Antichemical protective gear
Number of subjects: 24
Study 17157757 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (3000 mg/day)
Number of subjects: 27
Study 14596355 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 272
Study 14596355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 14596355 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in depressed patients
Number of subjects: 272
Study 14596355 — intervention group
Group type: COMPARATOR
Intervention: Control group in depressed patients
Number of subjects: 272
Study 10947749 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 45
Study 10947749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 10947749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia
Number of subjects: 45
Study 9065092 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine instillations (1 mg, annual scheme)
Number of subjects: 13
Study 9065092 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without bladder cancer and without vaccine instillations)
Number of subjects: 13
Study 1426667 — intervention group
Group type: EXPERIMENTAL
Intervention: Connaught BCG (ImmuCyst)
Number of subjects: 114
Study 1426667 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 114
Study 3971650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg)
Number of subjects: 6
Study 3971650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31127500 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day) administered 3 weeks on/1 week off
Number of subjects: 101
Study 28513088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Skeletal Muscle Area (SMA)
Number of subjects: 150
Study 28513088 — intervention group
Group type: COMPARATOR
Intervention: Psoas Muscle Area (PA)
Number of subjects: 150
Study 28513088 — intervention group
Group type: COMPARATOR
Intervention: Psoas Surface Area (PLW)
Number of subjects: 150
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong importance
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak importance
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong goal congruence
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak goal congruence
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong future expectation
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak future expectation
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong possibility
Number of subjects: 245
Study 25297455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak possibility
Number of subjects: 245
Study 23394517 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (200 mg p.o.)
Number of subjects: 0
Study 23394517 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (3-30 μM)
Number of subjects: 0
Study 23394517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20673559 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment
Number of subjects: 44
Study 20673559 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment
Number of subjects: 44
Study 19140911 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) ON
Number of subjects: 8
Study 19140911 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) OFF
Number of subjects: 8
Study 17197840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5 mg/kg bolus at induction, 2 mg/kg/h intraoperatively, 1.33 mg/kg/h for 24 h postoperatively)
Number of subjects: 40
Study 17197840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 40
Study 15249756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg/puff, 2 puffs every 12 h; n=27)
Number of subjects: 53
Study 15249756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=26)
Number of subjects: 53
Study 11581118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-free amino acid mixture
Number of subjects: 36
Study 11581118 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 36
Study 9727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen (Premarin 1.25 mg)
Number of subjects: 18
Study 9727072 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen (Estraderm 100TTS)
Number of subjects: 18
Study 9727072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and transdermal estrogen
Number of subjects: 18
Study 7953225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar DPX
Number of subjects: 24
Study 7953225 — intervention group
Group type: COMPARATOR
Intervention: Hologic QDR
Number of subjects: 24
Study 3135880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformable catheter
Number of subjects: 52
Study 3135880 — intervention group
Group type: COMPARATOR
Intervention: Control catheter
Number of subjects: 52
Study 30235496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 112
Study 30235496 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 112
Study 28638000 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group (SG)
Number of subjects: 30
Study 28638000 — intervention group
Group type: COMPARATOR
Intervention: Voluntary exercise group (VG)
Number of subjects: 30
Study 26088605 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized patient decision aid (P-DA) with usual care
Number of subjects: 74
Study 26088605 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 74
Study 23280269 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted home therapy
Number of subjects: 96
Study 23280269 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 96
Study 22127691 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 1008
Study 18166173 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifollicular vascularity assessment using power Doppler ultrasonography
Number of subjects: 60
Study 18166173 — intervention group
Group type: COMPARATOR
Intervention: Standard morphologic criteria
Number of subjects: 60
Study 17065108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 400 mg/day
Number of subjects: 40
Study 17065108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Skp2 overexpression
Number of subjects: 102
Study 12579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Skp2 overexpression and reduced p27kip1 expression
Number of subjects: 102
Study 12579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Skp2 expression in early stage (I, II) cases
Number of subjects: 102
Study 12579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Skp2 expression, tumor grade, tumor size, clinical stage
Number of subjects: 102
Study 10868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Lobe Score
Number of subjects: 108
Study 10868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Card Sorting Test (WCST)
Number of subjects: 108
Study 10868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Test
Number of subjects: 108
Study 9291301 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype G1 monovalent vaccine
Number of subjects: 0
Study 9291301 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype G1‐G4 tetravalent vaccine
Number of subjects: 0
Study 8349389 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program of smoking control, discouragement, and cessation
Number of subjects: 3
Study 8349389 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation only
Number of subjects: 3
Study 3792434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 15 mg
Number of subjects: 79
Study 3792434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 79
Study 3792434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 79
Study 3792434 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 79
Study 3792434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79